2-bis-(4-chlorobenzoyl)amino-3-bromo-1,4-naphthoquinone | 1421252-58-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-bis-(4-chlorobenzoyl)amino-3-bromo-1,4-naphthoquinone
• 英文别名: 2-bis(4-chlorobenzoyl)amino-3-bromo-1,4-naphthoquinone；N-(3-bromo-1,4-dioxonaphthalen-2-yl)-4-chloro-N-(4-chlorobenzoyl)benzamide
• CAS: 1421252-58-5
• 化学式: C₂₄H₁₂BrCl₂NO₄
• 分子量: 529.174
• InChiKey: OYVCWCJCCNXLGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氨基-3-溴萘-1,4-二酮 、 4-氯苯甲酰氯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 24.25h， 以34%的产率得到2-bis-(4-chlorobenzoyl)amino-3-bromo-1,4-naphthoquinone
  参考文献：
  名称：

  Synthesis and Characterization of Novel Unsymmetrical and Symmetrical 3-Halo- or 3-Methoxy-substituted 2-Dibenzoylamino-1,4-naphthoquinone Derivatives

  摘要：

  对称和不对称的3-卤代或3-甲氧基取代的2-二苯甲酰氨基-1,4-纳弗喹啉类似物通过氢化钠促进的双酰化反应合成，平均产率为45%，反应底物为2-氨基-3-氯-1,4-纳弗喹啉、2-氨基-3-溴-1,4-纳弗喹啉和2-氨基-3-甲氧基-1,4-纳弗喹啉。

  DOI：

  10.3390/molecules18021973

文献信息

• [EN] METHOD FOR INHIBITING TRYPANSOMA CRUZI<br/>[FR] PROCÉDÉ D'INHIBITION DE TRYPANSOMA CRUZI
  申请人：UNIV HOWARD

  公开号：WO2013016661A1

  公开（公告）日：2013-01-31

  In its broadest aspect, a method for treating a mammalian patient at risk or suffering from a disease caused by a kinetoplastid parasite comprises administering to such subject an effective kinetoplasticidal amount of an imido-substituted 1,4- naphthoquinone to inhibit the kinetoplastid. In an important aspect, a method of inhibiting Trypanosoma cruzi comprises administering to a patient for prophylaxis or to a patient in need of treatment an antitrypanosomal effective amount of an imido-substituted 1 A-naphthoquinone.

  在其最广泛的方面，一种治疗受威胁或患有由原生质体寄生虫引起的疾病的哺乳动物患者的方法包括向该受试者施用有效的威力质体杀灭剂量的亚胺取代的1,4-萘醌以抑制威力体。在一个重要方面，一种抑制克氏锥虫的方法包括向需要预防或治疗的患者施用亚胺取代的1 A-萘醌的抗克氏锥虫有效量。
• METHOD FOR INHIBITING TRYPANOSOMA CRUZI
  申请人：Bakare Oladapo

  公开号：US20150073177A1

  公开（公告）日：2015-03-12

  Methods are provided to inhibit proliferation of Trypanosoma cruzi with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can be used to provide prophylaxis or treatment to a patient in need of treatment against Chagas disease.
• VITAMIN C AND VITAMIN K COMPOUND FOR TREATING PANCREATIC CANCER
  申请人：IC-MedTech Corp.

  公开号：US20170333392A1

  公开（公告）日：2017-11-23

  Provided herein is a method of treating, preventing, or alleviating one or more symptoms of pancreatic cancer in a subject, comprising administering to the subject therapeutically effective amounts of (i) vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and (ii) a vitamin K compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
• ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE
  申请人：IC-MedTech Corp.

  公开号：US20190343794A1

  公开（公告）日：2019-11-14

  Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
• ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER
  申请人：IC-MedTech Corp.

  公开号：US20210283100A1

  公开（公告）日：2021-09-16

  Provided herein is a method of treating, preventing, or alleviating one or more symptoms of cancer in a subject, comprising administering to the subject a therapeutically effective amount of: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) a sodium glucose cotransporter inhibitor, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.